Literature DB >> 16757360

Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer.

Daniel G Rosen1, Gong Yang, Robert C Bast, Jinsong Liu.   

Abstract

The Ras gene family has been implicated in the development of many human epithelial cancers. Mutations in K-ras or its downstream mediator BRAF have been detected in about two thirds of low-grade serous carcinomas and borderline serous tumors; mutations in K-ras are also often present in benign and invasive mucinous ovarian cancers. Although the oncogenic allele H-ras(V12) is present in only approximately 6% of ovarian cancers, physiologically activated H-ras protein is commonly detected in human ovarian cancer, presumably because of an increase in upstream signals from tyrosine kinase growth factor receptors such as Her-2/neu, despite the lack of a Ras mutation. The mechanisms by which ras oncogenes transform human epithelial cells are not clear. The methods described here are what we use to culture human ovarian surface epithelial cells, to immortalize those cells, and to transform the immortalized cells with oncogenic H-ras or K-ras. These Ras-transformed human ovarian surface epithelial cells form tumors in nude mice and recapitulate many features of human ovarian cancer, thus providing an excellent model system for studying the initiation and progression of human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757360     DOI: 10.1016/S0076-6879(05)07052-7

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  8 in total

1.  The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.

Authors:  Gong Yang; Daniel G Rosen; Zhihong Zhang; Robert C Bast; Gordon B Mills; Justin A Colacino; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-23       Impact factor: 11.205

2.  Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.

Authors:  Breanne D W Karanikolas; Marxa L Figueiredo; Lily Wu
Journal:  Mol Cancer Res       Date:  2009-09-01       Impact factor: 5.852

3.  IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.

Authors:  A Rojas; G Liu; I Coleman; P S Nelson; M Zhang; R Dash; P B Fisher; S R Plymate; J D Wu
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

4.  Ovarian surface epithelium in patients with severe ovarian infertility: a potential source of cells expressing markers of pluripotent/multipotent stem cells.

Authors:  Irma Virant-Klun; Thomas Skutella; Martin Stimpfel; Jasna Sinkovec
Journal:  J Biomed Biotechnol       Date:  2011-12-06

5.  ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer.

Authors:  Brian Gloss; Kim Moran-Jones; Vita Lin; Maria Gonzalez; James Scurry; Neville F Hacker; Robert L Sutherland; Susan J Clark; Goli Samimi
Journal:  Mol Cancer       Date:  2014-01-06       Impact factor: 27.401

6.  Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness.

Authors:  Huijing Yin; Jingshu Wang; Hui Li; Yinjue Yu; Xiaoling Wang; Lili Lu; Cuiting Lv; Bin Chang; Wei Jin; Wenwen Guo; Chunxia Ren; Gong Yang
Journal:  Nat Commun       Date:  2021-07-09       Impact factor: 14.919

7.  Cancer-Associated Fibroblast-Derived Interleukin-8 Promotes Ovarian Cancer Cell Stemness and Malignancy Through the Notch3-Mediated Signaling.

Authors:  Zhaodong Ji; Wenjuan Tian; Wen Gao; Rongyu Zang; Huaying Wang; Gong Yang
Journal:  Front Cell Dev Biol       Date:  2021-07-01

8.  Transformation of human ovarian surface epithelial cells by Krüppel-like factor 8.

Authors:  H Lu; X Wang; A M Urvalek; T Li; H Xie; L Yu; J Zhao
Journal:  Oncogene       Date:  2012-12-10       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.